Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Macrophage TREM2 is a triglyceride-rich lipoprotein receptor that undergoes shedding in prediabetic hepatic steatosis
Jingjing Tang, Jenny E. Kanter, Baohai Shao, Masami Shimizu-Albergine, Farah Kramer, Ah Reum Khang, Jason Luo, Huaqing Zheng, Alan Tran, Jocelyn Cervantes, Jeremy M. Frey, Mauricio D. Dorfman, Cheng-Chieh Hsu, Laura J. den Hartigh, Tomas Vaisar, Brandon S.J. Davies, Adam E. Mullick, George N. Ioannou, Gordon I. Smith, Samuel Klein, Nicholas O. Davidson, Karin E. Bornfeldt
Jingjing Tang, Jenny E. Kanter, Baohai Shao, Masami Shimizu-Albergine, Farah Kramer, Ah Reum Khang, Jason Luo, Huaqing Zheng, Alan Tran, Jocelyn Cervantes, Jeremy M. Frey, Mauricio D. Dorfman, Cheng-Chieh Hsu, Laura J. den Hartigh, Tomas Vaisar, Brandon S.J. Davies, Adam E. Mullick, George N. Ioannou, Gordon I. Smith, Samuel Klein, Nicholas O. Davidson, Karin E. Bornfeldt
View: Text | PDF
Research Article Metabolism Vascular biology

Macrophage TREM2 is a triglyceride-rich lipoprotein receptor that undergoes shedding in prediabetic hepatic steatosis

  • Text
  • PDF
Abstract

Prediabetes is associated with increased production of triglyceride-rich lipoproteins (TRLs), cardiovascular disease (CVD), and hepatic steatosis, which is linked to increased plasma levels of soluble TREM2 (sTREM2), the shed domain of TREM2 (triggering receptor expressed on myeloid cells 2). Whether and how TREM2 shedding contributes to elevated TRLs is unknown. By complementary analyses of individuals with prediabetes and hepatic steatosis and preclinical models, we show that plasma sTREM2 levels correlate positively with plasma apolipoprotein C3 (APOC3), an apolipoprotein that slows TRL catabolism and predicts CVD risk. Individuals with prediabetes and hepatic steatosis had higher plasma concentrations of APOC3-rich TRLs 35 to 60 nm in diameter than healthy controls. Mouse models of prediabetes with hepatic steatosis revealed that the increased plasma concentrations of sTREM2, APOC3, and TRLs were due to activation of macrophage ADAM17, a TREM2 sheddase. Preserving macrophage full-length TREM2 protected against the elevated plasma APOC3, sTREM2, dyslipidemia, and atherosclerosis, whereas TREM2 deficiency increased APOC3, TRLs, and atherosclerosis. Mechanistically, full-length TREM2 mediates macrophage TRL uptake, preventing excessive hepatic APOC3-rich TRL release and atherosclerosis. Our findings identify macrophage TREM2 shedding as an upstream contributor to the elevated TRLs in hepatic steatosis, providing a mechanistic link between hepatic steatosis and CVD risk in prediabetes.

Authors

Jingjing Tang, Jenny E. Kanter, Baohai Shao, Masami Shimizu-Albergine, Farah Kramer, Ah Reum Khang, Jason Luo, Huaqing Zheng, Alan Tran, Jocelyn Cervantes, Jeremy M. Frey, Mauricio D. Dorfman, Cheng-Chieh Hsu, Laura J. den Hartigh, Tomas Vaisar, Brandon S.J. Davies, Adam E. Mullick, George N. Ioannou, Gordon I. Smith, Samuel Klein, Nicholas O. Davidson, Karin E. Bornfeldt

×

Figure 2

Plasma sTREM2 and APOC3 are increased in a mouse model of prediabetes and hepatic steatosis.

Options: View larger image (or click on image) Download as PowerPoint
Plasma sTREM2 and APOC3 are increased in a mouse model of prediabetes an...
(A) Plasma APOC3 and sTREM2 were measured by ELISAs in samples collected from Ldlr–/– mice fed a diabetogenic diet (DDC) for 0–2 weeks (n = 16), 3–5 weeks (n = 15), and 6–8 weeks (n = 10). (B–G) Plasma sTREM2, APOC3, triglycerides, cholesterol, free fatty acids (FFAs), and total APOB (measured by an antibody that binds to the N-terminus; APOB-Nt) levels in Ldlr–/– mice fed an SLD or DDC for 22 weeks. (H) Cholesterol lipoprotein profile at the 22-week time point. RLP, remnant lipoprotein particle. (I) TRLs were isolated from mouse plasma (d < 0.019 g/mL), and TRL subpopulation particle concentrations (TRL-P) and sizes were measured by ion mobility analysis. (J) Glucose tolerance tests at 20 weeks. (K) Plasma AST at 22 weeks. (L) Liver triglycerides. (M) Liver cholesterol. (N and O) Hepatocytes were isolated and analyzed for lipid loading (BODIPY) and viability (7AAD) by flow cytometry. (P and Q) Total TREM2 and cell surface TREM2 were measured by flow cytometry in permeabilized and non-permeabilized Kupffer cells (KCs), respectively, and infiltrated macrophages in the liver. Mean ± SEM (B–Q). Statistical analyses: Pearson’s correlation (A), Mann-Whitney (B–G and K–O), 2-way ANOVA with Šídák’s multiple-comparison test (I and J), 2-way ANOVA with Tukey’s multiple-comparison test (P and Q). See Supporting Data Values for group sizes and statistics.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts